Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Migraine meds put to the test in Real-World study

NCT ID NCT05827887

Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 226 adults in Israel who were prescribed ubrogepant or atogepant for their migraines. Researchers wanted to see how satisfied people were with these drugs in real-world settings, not just in a lab. Participants used an app to track their experience over 90 days, and the main goal was to measure treatment satisfaction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

226 people

The number who actually took part.

Started

Jun 2023

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants with migraine prescribed Ubrogepant or Atogepant by their physician.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of migraine according to the ICHD-3 upon judgement of the treating physician * The patients should be naive to the designated treatment * Ability to fill an e-diary app Exclusion Criteria: * Patients who cannot be treated with UBRO or ATO according to the applicable approved label * Patients participating in a concurrent clinical interventional study or within the last 30 days * Patients who were previously treated with rimegepant will be excluded from the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Migraine

Contacts and locations

Locations

  • Assuta Ashdod Medical Center /ID# 260020

    Ashdod, Southern District, 7747600, Israel

  • Clalit HMO /ID# 257364

    Gani Tikva, 5591236, Israel

  • Edith Wolfson Medical Center /ID# 269740

    Holon, Central District, 5822012, Israel

  • Hadassah Medical Center-Hebrew University /ID# 257352

    Jerusalem, 91120, Israel

  • Maccabi Healthcare Services /ID# 254171

    Kfar Saba, Central District, 4420123, Israel

  • Meir Medical Center /ID# 254170

    Kfar Saba, Central District, 4428164, Israel

  • Shaare Zedek Medical Center /ID# 254169

    Jerusalem, Jerusalem, 91031, Israel

  • Soroka University Medical Center /ID# 254551

    Beersheba, Southern District, 8410101, Israel

  • Tel Aviv Sourasky Medical Center /ID# 263089

    Tel Aviv, Tel Aviv, 6423906, Israel

  • The Chaim Sheba Medical Center /ID# 254550

    Ramat Gan, Tel Aviv, 5265601, Israel

  • ZIV Medical Center /ID# 257360

    Safed, Northern District, 13100, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.